1 recruiting. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
Follow Zelluna Immunotherapy AS: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies ZI-MA4-1 (TCR-NK cells), Cyclophosphamide, Fludarabine - Ovarian Cancer, Squamous Non-Small Cell Lung Cancer (NSCLC) | Phase 1 | Recruiting | Zelluna Immunotherapy AS | 9 | 2026-05-11 | 2026-09-04 |
Head and Neck Neoplasms (1) · Ovarian Neoplasms (1) · Sarcoma, Synovial (1)
Cyclophosphamide (1) · fludarabine (1)
United Kingdom (1)